MediWound (NASDAQ:MDWD) Cut to "Hold" at Zacks Research

Key Points

• MediWound was downgraded from a "strong-buy" to a "hold" rating by Zacks Research, reflecting a shift in analyst sentiment.
• The company reported a loss of ($1.23) earnings per share for its most recent quarter, missing analysts' expectations by ($0.68).
• MediWound has a market capitalization of $188.49 million and a consensus rating of "Moderate Buy" from several analysts, with an average target price of $32.25.

Zacks Research downgraded shares of MediWound (NASDAQ:MDWD - Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Several other equities analysts have also weighed in on MDWD. Oppenheimer started coverage on shares of MediWound in a research report on Monday, June 2nd. They set an "outperform" rating and a $34.00 price target for the company. Wall Street Zen lowered shares of MediWound from a "hold" rating to a "sell" rating in a research report on Friday, July 18th. Alliance Global Partners started coverage on shares of MediWound in a research report on Friday, May 2nd. They set a "buy" rating and a $25.00 target price for the company. Finally, HC Wainwright set a $31.00 target price on shares of MediWound and gave the stock a "buy" rating in a research report on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.25.

MediWound Stock Up 1.2%

MDWD traded up $0.21 during trading on Tuesday, hitting $17.60. 79,455 shares of the company traded hands, compared to its average volume of 75,790. The firm has a market cap of $190.26 million, a P/E ratio of -6.67 and a beta of 0.21. The stock's fifty day moving average is $19.29 and its 200 day moving average is $18.54. MediWound has a one year low of $14.14 and a one year high of $22.50.

MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.68). The company had revenue of $5.71 million for the quarter, compared to the consensus estimate of $5.68 million. MediWound had a negative net margin of 142.18% and a negative return on equity of 96.71%. On average, equities research analysts forecast that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 649 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 1,703 shares in the last quarter. Corebridge Financial Inc. lifted its holdings in shares of MediWound by 17.1% in the first quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock worth $71,000 after buying an additional 665 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock worth $85,000 after buying an additional 999 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of MediWound by 2,255.2% in the first quarter. Deutsche Bank AG now owns 6,312 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 6,044 shares in the last quarter. 46.83% of the stock is owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.